Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Development of a Luminescent Bioassay for Thyroid Stimulating Antibodies

Evans, C., Morgenthaler, N. G., Lee, S., Llewellyn, David H., Clifton-Bligh, R., John, Robert Anthony, Lazarus, John Henry, Chatterjee, V. K. K. and Ludgate, Marian Elizabeth 1999. Development of a Luminescent Bioassay for Thyroid Stimulating Antibodies. Journal of Clinical Endocrinology & Metabolism 84 (1) , pp. 374-377. 10.1210/jc.84.1.374

Full text not available from this repository.

Abstract

The hyperthyroidism of Graves Disease (GD) is due to thyroid stimulating antibodies (TSAb) which are thyrotropin (TSH) agonists. They are detected routinely by measuring their ability to inhibit TSH binding to the receptor (TBII), which does not reflect their true biological activity. Current bioassays which measure cAMP by RIA, are not suitable for routine use. We have developed a luminescent bioassay for TSAb, by introducing a cAMP responsive luciferase construct into CHO cells stably expressing the human TSH receptor (TSHR). Clone lulu1 displays dose dependent TSH response detectable from 10 μU/ml and maximal at 10 mU/ml when a >25 fold increase in light output is obtained. 34 euthyroid sera were tested to determine a reference range, with values >1.5 relative light units (R.L.U.) being considered positive. An international TSAb standard responded in a dose dependent manner with 10 mIU/ml giving an R.L.U. of >10. The assay was adapted to a 96 well format for automatic readout and 100 treated GD samples (50 TBII negative and 50 TBII positive) were tested, 73% being positive. In contrast only 4% of 79 control sera from individuals with Hashimoto’s, non-thyroid autoimmunity or multinodular goitre produced R.L.U. >1.5. When 44 of the GD sera were compared in a traditional salt-free bioassay, 61% were positive compared with 75% in the new luminescent assay. In conclusion, we have developed a luminescent bioassay for TSAb, using unfractionated serum which is capable of high throughput suitable for routine use.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Biosciences
Medicine
Subjects: Q Science > QR Microbiology
R Medicine > RM Therapeutics. Pharmacology
Publisher: The Endocrine Society
ISSN: 0021-972X
Last Modified: 30 Jun 2017 03:03
URI: http://orca.cf.ac.uk/id/eprint/46362

Citation Data

Cited 56 times in Google Scholar. View in Google Scholar

Actions (repository staff only)

Edit Item Edit Item